In this study, freshly procured tissue samples from women who have undergone hysterectomies as a course of treatment for uterine leiomyomas, confirmed to have a glycine-to-aspartate (G44D) or glycine-to-serine (G44S) substitution in exon 2 of MED12, are used to characterize epigenetic changes in the disease. Here, MED12 is linked to uterine corpus leiomyoma.